N@N

InVivo Therapeutics Submits IDE Application to FDA for Spinal Cord Injury Clinical Trial

_{//health-fitness.news-articles.net/content/2011/ .. o-fda-for-spinal-cord-injury-clinical-trial.html}
^{Published in Health and Fitness on Friday, July 8th 2011 at 4:05 GMT by Market Wire}  

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--InVivo Therapeutics (OTCBB: NVIV) today announced that the Company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for a proprietary biopolymer scaffolding device to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury.

"InVivoa™s first regulatory submission for human testing is a major step forward in realizing the promise of our technology for spinal cord injury patients"

The Company has requested permission to initiate an open-label study of 10 patients with acute spinal cord injuries within several days of injury. As currently planned, patients will be enrolled in the pilot trial at sites in Boston and Washington, D.C. under Principal Investigators Eric Woodard, M.D., InVivoa™s Chief Medical Officer and Chief of Neurosurgery at New England Baptist Hospital, and Jonathan Slotkin, M.D., neurosurgeon at Washington Brain & Spine Institute. Patients will subsequently be transferred to a rehabilitation center and will be followed for one year.

The trial will evaluate safety data as the primary endpoint. Motor and sensory recovery, as determined by the American Spinal Injury Association (ASIA) Impairment Score, will also be assessed as secondary endpoints.

aInVivoa™s first regulatory submission for human testing is a major step forward in realizing the promise of our technology for spinal cord injury patients,a said Frank Reynolds, Chief Executive Officer of InVivo Therapeutics. aWhile current procedures offer very little hope, we have seen evidence of functional recovery in our preclinical non-human primate studies that supports advancement to human trials. Our goal for this initial study is to safely minimize the secondary injury processes, thereby allowing the body to reorganize locally toward functional recovery through the spared healthy tissue. This process, known as neuroplasticity, may result in partial functional recovery.a

The InVivo investigational device is a biopolymer scaffold implant that will be customized by a neurosurgeon to fit the spinal cord lesion, and then implanted into the patienta™s spinal cord. The scaffold biodegrades within the body at a controlled rate over approximately 12 weeks.

In addition to the scaffold, InVivo is developing and testing its second product, an injectable hydrogel intended as a minimally invasive option to deliver agents locally.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companya™s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Companya™s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Companya™s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companya™s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 10-K, Form 10-Q and Form 8-K. We do not undertake to update these forward-looking statements made by us.